[Differential diagnosis between mechanical and inflammatory lower back pain, therapy options]

Area of Science:

• Rheumatology and Orthopedics
• Clinical Pharmacology

Background:

• Lower back pain is a common condition with diverse etiologies.
• Distinguishing between mechanical and inflammatory causes is crucial for effective treatment.
• Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used, necessitating safety and efficacy evaluations.

Purpose of the Study:

• To provide a differential diagnosis framework for mechanical versus inflammatory lower back pain.
• To compare the efficacy and safety of amtolmetinum guacilum (AMG) and celecoxib.
• To discuss the cardiovascular safety and efficacy of AMG in ankylosing spondylitis patients, referencing the CORONA study.

Main Methods:

• Review of clinical and paraclinical evidence for differential diagnosis.
• Comparative analysis of studies involving amtolmetinum guacilum (AMG) and celecoxib.
• Inclusion of data from the CORONA study on ankylosing spondylitis treatment.

Main Results:

• Established criteria for differentiating mechanical and inflammatory lower back pain.
• Comparative efficacy and safety profiles of AMG and celecoxib presented.
• Cardiovascular safety and efficacy data for AMG in ankylosing spondylitis analyzed.

Conclusions:

• Accurate differential diagnosis aids in targeted therapeutic strategies for lower back pain.
• AMG and celecoxib demonstrate distinct efficacy and safety considerations.
• AMG shows potential for managing ankylosing spondylitis with acceptable cardiovascular safety.